Please provide your email address to receive an email when new articles are posted on . The accompanying cover story summarizes some pioneering activities in collagen cross-linking for keratoconus. In ...
On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...
Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and ...
SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase ...
Glaukos (GKOS) announced the submission of its New Drug Application NDA to the U.S. Food and Drug Administration FDA or Epioxa or Epi-on, its next-generation corneal cross-linking iLink therapy for ...
(MASS APPEAL) – If you’ve been diagnosed with Keratoconus then Corneal Cross Linking might get you back to better eyesight. Mass Appeal’s Patrick Berry joined Dr. John P. Frangie, MD to learn more.
Corneal cross-linking is an in-office procedure that works to strengthen and stabilize the cornea in eyes that have weakness from keratoconus or ectasia. At Baylor Medicine, our cornea specialists are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results